Transcriptome-guided development of a fibrosis-reversal compound reduces skin scarring and allows regeneration via mitochondrial uncoupling [RNA-seq]

Current therapies show limited efficacy and cause iatrogenic dermal disruption (e.g., triamcinolone acetonide, a first-line corticosteroid for keloids), with topical medications demonstrating inferior outcomes. Through transcriptome-guided evaluation, we develop FR-1 (fibrosis-reversal compound 1), a small molecule that reverses fibrosis in vitro by inhibiting fibroblast proliferation, suppressing α-SMA, and remodeling the ECM via collagen downregulation and MMP1 induction.

In a murine linear excisional wound model, daily topical FR-1 application progressively reduces scar area. Notably, unlike triamcinolone acetonide, FR-1 avoids skin atrophy and hair follicle damage. Comprehensive safety evaluations, druggability and skin permeation assessments, and studies utilizing patient-derived keloid ex vivo explants and in vivo xenografts demonstrate its translational potential.